P. Jones

Nicole E. Jelesoff, C. Ballantyne, J. Guyton, 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Management of Lp(a).

C. Ballantyne, S. Marcovina, W. Brown, 2010, Journal of clinical lipidology.

Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system

A. Gotto, S. Kelsey, D. Illingworth, 1998 .

A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience.

C. Ballantyne, S. Virani, Anum Saeed, 2017, Journal of clinical lipidology.

Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels.

E. Schaefer, E. Stein, B. Asztalos, 2009, Atherosclerosis.

Treating dyslipidemia in the high-risk patient.

P. Jones, 2010, The Journal of family practice.

Clinical Lipidology Roundtable Discussion Management of Lp(a)

C. Ballantyne, S. Marcovina, W. Brown, 2010 .

Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse.

C. Ballantyne, S. Virani, Anum Saeed, 2018, Journal of clinical lipidology.

Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.

P. Jones, Peter H. Jones, 2004, American heart journal.

Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT.

D. Azagury, N. Nguyen, S. Kothari, 2016, Journal of clinical lipidology.

The power of statins: aggressive lipid lowering.

P. Jones, 2002, Postgraduate medicine.

L-γ-Glutamyl Dopamine, an Oral Dopamine Prodrug with Renal Selectivity

P. Jones, J. Kyncl, F. Minard, 1979 .

Metabolism of γ-glutamyl dopamide and its carboxylic acid esters☆

P. Jones, J. Kyncl, J. Cain, 1980 .

Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.

S. Leal, J. Belmont, C. Ballantyne, 2011, Atherosclerosis.

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

M. Koschinsky, B. Nordestgaard, C. McNeal, 2022, Journal of clinical lipidology.

Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study.

E. Boerwinkle, J. Coresh, C. Ballantyne, 2019, Atherosclerosis.

Medical Management of Serum Lipids and Coronary Heart Disease

C. Ballantyne, R. Dadu, Y. Pokharel, 2015 .

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).

J. Mckenney, M. McGovern, H. Bays, 2007, Atherosclerosis.

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.

M. Davidson, P. Jones, Peter H. Jones, 2005, The American journal of cardiology.

Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit

P. Jones, F. McTaggart, Peter H. Jones, 2008, Cardiovascular Drugs and Therapy.

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Elinor Miller, J. Mckenney, E. Stein, 2003, The American journal of cardiology.

Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.

P. Jones, Peter H. Jones, 2007, The American journal of cardiology.

Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A Retrospective Analysis

K. Thakker, P. Jones, Radhika Nair, 2012, Journal of the American Heart Association.

National Lipid Association Annual Summary of Clinical Lipidology 2015.

H. Bays, W. Brown, P. Jones, 2014, Journal of clinical lipidology.

The use of statins in acute coronary syndromes: The mechanisms behind the outcomes

J. Plana, P. Jones, Peter H. Jones, 2001, Current atherosclerosis reports.

National Lipid Association Annual Summary of Clinical Lipidology 2016.

J. Mckenney, A. Goldberg, H. Bays, 2016, Journal of clinical lipidology.

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.

I. Holme, R. Upmanyu, M. V. van Hessen, 2014, European heart journal.

Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system.

C. Ballantyne, R. Hoogeveen, Ron C Hoogeveen, 2005, Clinical chemistry.

A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease.

C. Ballantyne, E. Schaefer, S. Virani, 2013, Journal of clinical lipidology.

National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.

J. Mckenney, S. Grundy, Matthew K. Ito, 2015, Journal of clinical lipidology.

Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.

M. Corson, M. Davidson, P. Jones, 2008, The American journal of cardiology.

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.

J. Mckenney, S. Grundy, S. Daniels, 2015, Journal of clinical lipidology.

Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.

E. Schaefer, E. Stein, K. Nakajima, 2011, The American journal of cardiology.

The metabolic syndrome and type 2 diabetes: role of the adipocyte

R. McPherson, P. Jones, Peter H. Jones, 2003, Current opinion in lipidology.

Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.

Jeffrey L. Anderson, P. Gorelick, M. Alberts, 2008, The American journal of cardiology.

Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial

J. Mckenney, P. Jones, V. Cain, 2003, Current medical research and opinion.

Optimizing Cardiovascular Outcomes in Patients with Type 2 Diabetes— Clinical Implications of the FIELD Results

P. Jones, Peter H. Jones, 2006 .

Clinical Pharmacokinetics of Pravastatin

J. Quion, P. Jones, Peter H. Jones, 1994, Clinical pharmacokinetics.

Low serum cholesterol increases the risk of noncardiovascular events: An antagonist viewpoint

P. Jones, 1994, Cardiovascular Drugs and Therapy.

Complementary Therapy to Target LDL Cholesterol: The Role of the Ezetimibe/Simvastatin Combination

P. Jones, R. C. Neal, Peter H. Jones, 2006, Vascular health and risk management.

D. Azagury, N. Nguyen, S. Kothari, 2016, Journal of clinical lipidology.

Diet and pharmacologic therapy of obesity to modify atherosclerosis

P. Jones, Peter H. Jones, 2000, Current atherosclerosis reports.

Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.

A. Goldberg, H. Knapp, C. Setze, 2010, American heart journal.

National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.

J. Mckenney, S. Grundy, Matthew K. Ito, 2014, Journal of clinical lipidology.

Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.

R. Rosenson, M. Davidson, K. Thakker, 2012, Journal of clinical lipidology.

Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety

P. Jones, E. Roth, T. Jacobson, 2010 .

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.

K. Ferdinand, D. Hunninghake, E. Stein, 2004, Clinical therapeutics.

Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.

P. Jones, Peter H. Jones, 2008, The American journal of cardiology.

Lipid-Lowering Treatment in Coronary Artery Disease

P. Jones, Peter H. Jones, 2000, Drugs.

Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia

J. Mckenney, L. Williams, A. Gold, 2010, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Statins: the case for higher, individualized starting doses.

P. Jones, Peter H. Jones, 2005, Cleveland Clinic journal of medicine.

Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention: the search for superior treatment.

P. Jones, Peter H. Jones, 2004, The American journal of medicine.

Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study.

J. Spertus, J. O’Keefe, S. Virani, 2017, Journal of clinical lipidology.

Evidence of Altered Cardiac Electrophysiology Following Prolonged Androgenic Anabolic Steroid Use

F. Grace, N. Sculthorpe, B. Davies, 2010, Cardiovascular Toxicology.

The effect of short-term creatine loading on active range of movement.

F. Grace, N. Sculthorpe, I. Fletcher, 2010, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline.

K. Nasir, C. Ballantyne, L. Steinberg, 2016, Atherosclerosis.

Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.

J. Mckenney, D. Karalis, P. Jones, 2005, American heart journal.

A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin

H. Bays, H. Schrott, R. Knopp, 1998, Journal of cardiovascular pharmacology and therapeutics.

A dataset to assess providers׳ knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline

K. Nasir, C. Ballantyne, L. Steinberg, 2016, Data in brief.

Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies

Jennifer G. Robinson, H. Colhoun, H. Bays, 2014, Clinical cardiology.

Dyslipidemia in older adults.

P. Jones, Peter H. Jones, 2006, The American journal of geriatric cardiology.

Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.

J. O'donnell, P. Jones, M. Hirsch, 2005, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Reduction of LDL-C by more than 60% with the HMG-CoA reductase inhibitor atorvastatin

D. Sprecher, S. Schwartz, H. Haber, 1994 .

Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training.

C. Ballantyne, L. Steinberg, S. Virani, 2012, Journal of clinical lipidology.

Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides

C. Ballantyne, K. Thakker, C. Setze, 2011, Cardiovascular Drugs and Therapy.

Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins

H. Bays, M. Davidson, C. Setze, 2008, Clinical drug investigation.

Provider understanding of the 2013 ACC/AHA cholesterol guideline.

C. Ballantyne, L. Steinberg, S. Virani, 2016, Journal of clinical lipidology.

CD11c Expression in Adipose Tissue and Blood and Its Role in Diet-Induced Obesity

J. Perrard, C. Smith, C. Ballantyne, 2010, Arteriosclerosis, thrombosis, and vascular biology.